Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels

Gynecologic Oncology

Volumn 123, Issue 2, 2011, Pages 295-300

  Coticchia, Christine M ^a,b   Curatolo, Adam S ^a   Zurakowski, David ^a   Yang, Jiang ^a,b   Daniels, Kathryn E ^c   Matulonis, Ursula A ^b,c   Moses, Marsha A ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Biomarkers; Matrix metalloproteinases; Neutrophil gelatinase associated lipocalin; Ovarian cancer

Indexed keywords

CA 125 ANTIGEN; GELATINASE A; GELATINASE B; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYMURIA; FEMALE; GEL ELECTROPHORESIS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

ACUTE-PHASE PROTEINS; ADULT; AGED; AREA UNDER CURVE; CA-125 ANTIGEN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIPOCALINS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 80054758418     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2011.07.034     Document Type: Article

References (28)

1. S.A. Cannistra Cancer of the ovary N Engl J Med 351 2004 2519 2529
2. J. Liu, and U. Matulonis Rational use of cytotoxic chemotherapy for recurrent ovarian cancer J Natl Compr Canc Netw 4 2006 947 953
3. V. Nosov, F. Su, M. Amneus, M. Birrer, T. Robins, and J. Kotlerman Validation of serum biomarkers for detection of early-stage ovarian cancer Am J Obstet Gynecol 200 639 2009 e1 e5
4. I. Visintin, Z. Feng, G. Longton, D.C. Ward, A.B. Alvero, and Y. Lai Diagnostic markers for early detection of ovarian cancer Clin Cancer Res 14 2008 1065 1072
5. Z. Yurkovetsky, S. Skates, A. Lomakin, B. Nolen, T. Pulsipher, and F. Modugno Development of a multimarker assay for early detection of ovarian cancer J Clin Oncol 28 2010 2159 2166
6. J.M. Riedinger, F. Bonnetain, J.P. Basuyau, N. Eche, H. Larbre, and I. Dalifard Change in CA 125 levels after the first cycle of induction chemotherapy is an independent predictor of epithelial ovarian tumour outcome Ann Oncol 18 2007 881 885
7. J.M. Niloff, R.C. Knapp, E. Schaetzl, C. Reynolds, and R.C. Bast Jr. CA125 antigen levels in obstetric and gynecologic patients Obstet Gynecol 64 1984 703 707
8. S. Paramasivam, L. Tripcony, A. Crandon, M. Quinn, I. Hammond, and D. Marsden Prognostic importance of preoperative CA-125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study J Clin Oncol 23 2005 5938 5942
9. I. Jacobs, and R.C. Bast Jr. The CA 125 tumour-associated antigen: a review of the literature Hum Reprod 4 1989 1 12
10. T.L. Klug, R.C. Bast Jr. , J.M. Niloff, R.C. Knapp, and V.R. Zurawski Jr. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas Cancer Res 44 1984 1048 1053
11. M.A. Moses, D. Wiederschain, K.R. Loughlin, D. Zurakowski, C.C. Lamb, and M.R. Freeman Increased incidence of matrix metalloproteinases in urine of cancer patients Cancer Res 58 1998 1395 1399
12. L.W. Chan, M.A. Moses, E. Goley, M. Sproull, T. Muanza, and C.N. Coleman Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy J Clin Oncol 22 2004 499 506
13. R. Roy, G. Louis, K.R. Loughlin, D. Wiederschain, S.M. Kilroy, and C.C. Lamb Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species Clin Cancer Res 14 2008 6610 6617
14. E.R. Smith, D. Zurakowski, A. Saad, R.M. Scott, and M.A. Moses Urinary biomarkers predict brain tumor presence and response to therapy Clin Cancer Res 14 2008 2378 2386
15. S.E. Pories, D. Zurakowski, R. Roy, C.C. Lamb, S. Raza, and A. Exarhopoulos Urinary metalloproteinases: noninvasive biomarkers for breast cancer risk assessment Cancer Epidemiol Biomarkers Prev 17 2008 1034 1042
16. R. Roy, B. Zhang, and M.A. Moses Making the cut: protease-mediated regulation of angiogenesis Exp Cell Res 312 2006 608 622
17. R. Roy, J. Yang, and M.A. Moses Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer J Clin Oncol 27 2009 5287 5297
18. N. Karahan, M. Guney, S. Baspinar, B. Oral, N. Kapucuoglu, and T. Mungan Expression of gelatinase (MMP-2 and MMP-9) and cyclooxygenase-2 (COX-2) in endometrial carcinoma Eur J Gynaecol Oncol 28 2007 184 188
19. C.A. Fernandez, L. Yan, G. Louis, J. Yang, J.L. Kutok, and M.A. Moses The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients Clin Cancer Res 11 2005 5390 5395
20. J. Yang, D.R. Bielenberg, S.J. Rodig, R. Doiron, M.C. Clifton, and A.L. Kung Lipocalin 2 promotes breast cancer progression Proc Natl Acad Sci USA 106 2009 3913 3918
21. J. Yang, and M.A. Moses Lipocalin 2: a multifaceted modulator of human cancer Cell Cycle 8 2009 2347 2352
22. M. Pepe The statistical evaluation of medical tests for classification and prediction 2003 Oxford University Press New York
23. F. Harrell Regression modeling strategies with applications to linear models, logistic regression, and survival analysis 2001 Springer New York, NY
24. D.X. Chen, P.E. Schwartz, X.G. Li, and Z. Yang Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses Obstet Gynecol 72 1988 23 27
25. S.A. Cannistra, U.A. Matulonis, R.T. Penson, J. Hambleton, J. Dupont, and H. Mackey Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 2007 5180 5186
26. G.J. Rustin, M.E. van der Burg, C.L. Griffin, D. Guthrie, A. Lamont, and G.C. Jayson Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 2010 1155 1163
27. R.T. Morris, and B.J. Monk Ovarian cancer: relevant therapy, not timing, is paramount Lancet 376 2010 1120 1122
28. N.D. Fleming, I. Cass, C.S. Walsh, B.Y. Karlan, and A.J. Li CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer Gynecol Oncol 121 2011 249 252